Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech IncfiledCriticalGenentech Inc
Priority claimed from PCT/US1995/003760external-prioritypatent/WO1995028173A1/en
Publication of MXPA96004802ApublicationCriticalpatent/MXPA96004802A/en
Publication of MX9604802ApublicationCriticalpatent/MX9604802A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.
MX9604802A1995-03-301995-03-30Treatment of congestive heart failure.
MX9604802A
(en)